---
title: "Altimmune, Inc. (ALT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/ALT.US.md"
symbol: "ALT.US"
name: "Altimmune, Inc."
industry: "Biotechnology"
datetime: "2026-05-21T16:51:02.150Z"
locales:
  - [en](https://longbridge.com/en/quote/ALT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/ALT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/ALT.US.md)
---

# Altimmune, Inc. (ALT.US)

## Company Overview

Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [altimmune.com](https://altimmune.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:16.000Z

**Overall: C (0.48)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 124 / 385 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 80.00% |  |
| Net Profit YoY | -0.93% |  |
| P/B Ratio | 1.29 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 366896599.14 |  |
| Revenue | 36000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -42.75% | E |
| Profit Margin | -253002.78% | E |
| Gross Margin | 0.00% | E |
| Revenue YoY | 80.00% | A |
| Net Profit YoY | -0.93% | C |
| Total Assets YoY | 113.42% | A |
| Net Assets YoY | 99.76% | A |
| Cash Flow Margin | 78.65% | C |
| OCF YoY | 80.00% | A |
| Turnover | 0.00 | E |
| Gearing Ratio | 15.39% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Altimmune, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "80.00%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-0.93%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.29",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "366896599.14",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "36000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-42.75%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-253002.78%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        },
        {
          "name": "Revenue YoY",
          "value": "80.00%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "-0.93%",
          "rating": "C"
        },
        {
          "name": "Total Assets YoY",
          "value": "113.42%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "99.76%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "78.65%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "80.00%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        },
        {
          "name": "Gearing Ratio",
          "value": "15.39%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.03 | 346/385 | - | - | - |
| PB | 1.29 | 113/385 | 3.01 | 2.19 | 1.95 |
| PS (TTM) | 10191.57 | 303/385 | 26607.31 | 17474.94 | 11606.82 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Kiniksa Pharmaceuticals (KNSA.US) | B | A | A | B | A | A |
| 02 | Arbutus Pharma (ABUS.US) | A | A | A | A | B | A |
| 03 | Rigel Pharma (RIGL.US) | A | A | B | A | B | A |
| 04 | Spero Therap (SPRO.US) | A | A | B | A | B | A |
| 05 | CapForce Inc. (CFOR.US) | B | A | A | A | B | A |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 6 | 60% |
| Overweight | 2 | 20% |
| Hold | 2 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.83 |
| Highest Target | 28.00 |
| Lowest Target | 2.50 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/ALT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/ALT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/ALT.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/ALT.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**